Neiloufar Family
VP, Health Solutions at Eleusis
Data updated
Research Footprint
Neiloufar Family appears in 7 tracked papers (2015–2023), most studied alongside LSD and Placebo, across Healthy Volunteers, Microdosing and Neurocognitive Disorders.
Most-cited paper: The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial (167 citations).
Frequent co-authors: Luke Williams, David Luke and Robin Carhart-Harris.
Background & Research
Neiloufar Family is a researcher and executive in psychedelic medicine who previously worked on language and cognition as a postdoctoral fellow at the University of Kaiserslautern. She later led and oversaw LSD studies at Eleusis, including work on semantic activation, time perception, and phase 1 safety and pharmacology trials in healthy volunteers.
Key Impact
She is notable for leading and co-authoring early human LSD studies spanning language, time perception, and safety/tolerability, helping establish modern clinical evidence around low-dose and microdose LSD.
Collaboration Network
17 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Neiloufar Family is associated with.
Eleusis
Imperial College London
academicThe Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →